Stemline Therapeutics, Inc.:
3 clinical stage oncology product candidates. 1) ELZONRIS is a targeted therapy directed to IL-3 receptor (CD123) present on range of malignancies that successfully completed a pivotal trial in BPDCN and was granted breakthrough designation; BLA accepted, granted FDA priority review, PDUFA date of Feb 21, 2019. ELZONRIS also evaluated in chronic myelomonocytic leukemia, myelofibrosis et al. 2) SL-801 is an oral small molecule reversible inhibitor of XPO1 in Ph 1 trial of pts w advanced solid tumors. 3) SL-701 is an immunotherapeutic that completed Ph 2 trial in pts w/2nd line GBM.
750 Lexington Ave
New York, NY 10022
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by